Jamie Ducharme

Jamie Ducharme is a health correspondent at TIME. She covers a wide range of topics including the COVID-19 pandemic, Long COVID, mental health, vaping, psychedelics and more. Her work for TIME has won awards from the Deadline Club, the New York Press Club and the Newswomen's Club of New York. Jamie is also the author of Big Vape: The Incendiary Rise of Juul which was adapted for a forthcoming Netflix docuseries. She has been with TIME since 2018.

Biography:  https://time.com/author/jamie-ducharme/

88%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

95%

Examples:

  • Jamie Ducharme tends to present information in a balanced and objective manner.

Conflicts of Interest

90%

Examples:

  • In both articles, Jamie discloses her affiliation with TIME and her role as a health correspondent without any conflict of interest.
  • There is no evidence of Jamie having any financial or personal conflicts of interest in her reporting.

Contradictions

75%

Examples:

  • In one article, Jamie reports that Paxlovid did not improve key Long COVID symptoms better than a placebo despite it being previously seen as a promising treatment for Long COVID.
  • Jamie also reports that taking Paxlovid for 15 days was safe but did not improve key Long COVID symptoms better than a placebo.

Deceptions

80%

Examples:

  • In one article, Jamie reports that taking Paxlovid for 15 days was safe but did not improve key Long COVID symptoms better than a placebo.
  • Jamie also mentions that despite the relative improvement, moderate and severe symptoms were still common at the end of the study.

Recent Articles

Meta-Analysis Reveals Early Use of Antivirals Reduces Long COVID Risk by 23%: Further Research Needed

Meta-Analysis Reveals Early Use of Antivirals Reduces Long COVID Risk by 23%: Further Research Needed

Broke On: Saturday, 08 June 2024 A meta-analysis of nine studies found that early use of antiviral drugs like Paxlovid and molnupiravir reduces the risk of long COVID by 23%. However, a recent Stanford University study failed to show significant benefits for Paxlovid in reducing long COVID symptoms. Further research is needed to determine antivirals' effectiveness. Long COVID, characterized by fatigue, brain fog, and other symptoms lasting weeks or months after infection, may be prevented with early antiviral intervention.
Second Human Case of Bird Flu Identified in Michigan: H5N1 Virus Circulating Among Cows

Second Human Case of Bird Flu Identified in Michigan: H5N1 Virus Circulating Among Cows

Broke On: Thursday, 23 May 2024 A second human case of bird flu has been identified in a Michigan farmworker, raising concerns over potential human-to-human transmission. The H5N1 virus has been spreading among birds and mammals worldwide since January 2022, affecting nearly 91 million in the US alone. The CDC advises limiting exposure to sick or dead animals and their waste, and provides guidance for poultry and livestock farmers on personal protective equipment. While the risk to the general public remains low if human infections remain sporadic without person-to-person spread, public health officials are closely monitoring the situation.